Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
暂无分享,去创建一个
Y. Mutoh | H. Mikamo | Hideo Kato | T. Ichihara | Takahito Mizuno | T. Umemura | Y. Ikeda | M. Hagihara | T. Yamada
[1] Connie M. Rhee,et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) , 2022, Diabetes care.
[2] M. Sise,et al. A Propensity Score–Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease , 2021, Kidney360.
[3] J. Skarbinski,et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.
[4] T. Hirai,et al. Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction , 2021, CPT: pharmacometrics & systems pharmacology.
[5] B. Cicali,et al. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort , 2020, Antimicrobial Agents and Chemotherapy.
[6] O. Tsang,et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[7] R. Bhattacharyya,et al. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.
[8] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[9] S. Cammarata,et al. Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment , 2018, Journal of clinical pharmacology.
[10] R. Turner,et al. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review. , 2015, International journal of antimicrobial agents.
[11] 高橋 聡,et al. Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .
[12] Wellbutrin,et al. Prescribing Information , 2015, European journal of haematology.